Govt moves to make three key cancer drugs cheaper
- Haji Ali dargah will have to open doors for women after Bombay HC ruling
- My vision for India is rapid transformation, not gradual evolution: PM Modi
- Panel works on alternative to pellets: Balls of pepper, capsicum gas
- Scorpene leak: Firms to be blacklisted only in cases of clear criminality, says Parrikar
- Sheena Bora murder: Taped conversations emerging on media submitted in court, says CBI
In a move that will benefit thousands of cancer patients but is likely to upset pharma MNCs, the Department of Pharmaceuticals has started the process of issuing compulsory licences for three commonly used anti-cancer drugs, Trastuzumab (or Herceptin, used for breast cancer), Ixabepilone (used for chemotherapy) and Dasatinib (used to treat leukaemia).
Compulsory licensing (CL) by the government allows a domestic company to manufacture and sell a generic version of a patented drug with or without the consent of the patent-holder. Sections 84 and 92 of the Indian Patents Act, 1970, provide for CL in cases where the patented drug is unavailable, unaffordable, or if there are problems with its supply in India. CL reduces the price of a drug manifold, and is a practice in many developing countries.
The first drug to be issued a compulsory licence in India was Bayer's Nexavar (sorafenib tosylate), a drug for liver cancer, last August. After the CL, Nexavar is available for Rs 8,880 per pack of 120 tablets (a month's dose), over 95% cheaper than its pre-CL price.
Trastuzumab, Ixabepilone and Dasatinib are all more expensive that Nexavar, costing Rs 50,000, Rs 70,000-80,000 and Rs 15,000 respectively for a month's dose.
- Pakistan army has a battle to win: The corruption within
- Anger of Irom Sharmila’s supporters should not be dismissed as selfishness or cynicism
- You keep the cow’s tail: A post card from Una, Gujarat, August 15
- History shows why Balochistan is not an internal matter of Pakistan
- The use of technology will be key to making GST a success
- Sedition law cannot be used against honest views, expressed peacefully